BYSI רווח למניה בשנים עשר החודשים האחרונים BeyondSpring Inc

BeyondSpring Inc. (BYSI) is implementing predictive software and laboratory automation to discover molecules targeting lung cancer. Net income per share over the last 12 months (TTM) reflects profit dynamics, while -0.16 shows the current volume of this metric. The firm relies on partnerships with pharma behemoths regarding plinabulin and generates revenue from the procurement of neutropenia drugs by insurance funds.

BeyondSpring Inc. (BYSI) is developing a specialized oncology drug business utilizing a virtual management model. By analyzing net income per share, an investor can determine the actual earnings remaining per security after all expenses are deducted. This indicator isolates the overall financial result from the impact of the total shares outstanding. For a company utilizing outsourced testing, this metric confirms the efficiency of long-term vendor contracts. Steady growth in this metric indicates the fundamental stability of the operating model.